I hope you're not about to tell me that this company might be able to make a profit. Even with it missing not only the primary endpoint in its latest trial, but also a number of secondary endpoints? I mean, this drug looks like a dud.
Anyway, if what you're implying is true, then I would have to raise my price target. How much it goes above cash value would depend on your sage advice.
I hope you're not about to tell me that this company might be...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
